Home » Authors » Peter O'Donnell

Articles by Peter O'Donnell

Galapagos Makes Progress with Glaxo and Janssen

Jan. 21, 2009

By Peter O'Donnell

Galapagos And Merck Join Forces in Diabetes, Obesity

Jan. 14, 2009

By Peter O'Donnell

European Parliament Ponders GM Approval Improvements

Jan. 14, 2009

By Peter O'Donnell

Small EU Biofirms Benefit from Special Assistance

Jan. 7, 2009

By Peter O'Donnell

Report from Europe: EMEA's 2009 plan includes additional help for industry

Jan. 6, 2009

By Peter O'Donnell

EMEA 2009 Plan Includes More Help for the Industry

Dec. 31, 2008

By Peter O'Donnell

Galapagos Expands Deals with GSK and Amgen

Dec. 24, 2008

By Peter O'Donnell

New European 'Pharma Vision' Has Something for Everyone

Dec. 17, 2008

By Peter O'Donnell

European Industry Impatient with the GMO Reform Bid

Dec. 10, 2008

By Peter O'Donnell

European Stem Cell Foes Rejoice at WARF Ruling

Dec. 3, 2008

By Peter O'Donnell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...